• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To Henry Schein (HSIC) Distributing DermaSensor’s Skin Cancer Detection Device

    Simply Wall St·09/06/2026 09:22:16
    Listen to the news
    • In early September 2026, DermaSensor Inc. announced it had made Henry Schein an approved supplier for its FDA-cleared handheld skin cancer detection device, broadening access across U.S. primary care, enterprise healthcare, and federal healthcare systems.
    • This supplier relationship underscores Henry Schein’s role as a key distribution and technology partner for innovative diagnostic tools in frontline medical settings.
    • We’ll now explore how Henry Schein’s role in distributing DermaSensor’s skin cancer detection device fits into and potentially reshapes its investment narrative.

    We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    Henry Schein Investment Narrative Recap

    To own Henry Schein, you need to believe it can keep shifting its mix toward higher margin technology and specialty offerings while executing a complex leadership and cost‑savings transition. The DermaSensor supplier agreement supports the technology and diagnostics angle, but on its own it does not meaningfully change the key near term swing factors: execution on the value creation program and the risk that pricing pressure and customer bargaining power continue to squeeze margins.

    Among recent developments, the creation of the Henry Schein Leadership Team and broader governance refresh in mid 2026 is particularly relevant. It frames how new leadership might prioritize partnerships like DermaSensor within a wider push to integrate global supply chain and distribution, pursue over US$100 million in cost savings, and support the targeted shift toward higher return businesses that underpin the current investment thesis.

    Yet, while partnerships like DermaSensor can support the story, investors should also be aware of how ongoing pricing pressure and large customer bargaining power could...

    Read the full narrative on Henry Schein (it's free!)

    Henry Schein's narrative projects $15.4 billion revenue and $661.2 million earnings by 2029.

    Uncover how Henry Schein's forecasts yield a $97.56 fair value, a 9% upside to its current price.

    Exploring Other Perspectives

    HSIC 1-Year Stock Price Chart
    HSIC 1-Year Stock Price Chart

    The most bearish analysts saw Henry Schein only reaching about US$15.1 billion in revenue and US$637.3 million in earnings by 2029, so if you worry that heavier exposure to government and Home Solutions contracts could crimp margins even as new tools like DermaSensor roll out, it is worth comparing that more pessimistic view with your own expectations.

    Explore 2 other fair value estimates on Henry Schein - why the stock might be worth just $97.56!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Interested In Other Possibilities?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.